Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jun 2;25(6):euad147.
doi: 10.1093/europace/euad147.

Pulsed field ablation using focal contact force-sensing catheters for treatment of atrial fibrillation: acute and 90-day invasive remapping results

Ante Anić  1 , Thomas Phlips  2 , Toni Brešković  1 , Pieter Koopman  2 , Steven Girouard  3 , Vikramaditya Mediratta  3 , Zrinka Jurišić  1 , Ivan Sikirić  1 , Lucija Lisica  1 , Johan Vijgen  2
Affiliations
Multicenter Study

Pulsed field ablation using focal contact force-sensing catheters for treatment of atrial fibrillation: acute and 90-day invasive remapping results

Ante Anić et al. Europace. .

Abstract

Aims: Pulsed field ablation (PFA) has emerged as a promising alternative to thermal ablation for treatment of atrial fibrillation (AF). We report performance and safety using the CENTAURI™ System (Galvanize Therapeutics) with three commercial, focal ablation catheters.

Methods and results: ECLIPSE AF (NCT04523545) was a prospective, single-arm, multi-centre study evaluating safety and acute and chronic pulmonary vein isolation (PVI) durability using the CENTAURI System in conjunction with the TactiCath SE, StablePoint, and ThermoCool ST ablation catheters. Patients with paroxysmal or persistent AF were treated at two centres. Patients were analysed in five cohorts based upon ablation settings, catheter, and mapping system. Pulsed field ablation was performed in 82 patients (74% male, 42 paroxysmal AF). Pulmonary vein isolation was achieved in 100% of pulmonary veins (322/322) with first-pass isolation in 92.2% (297/322). There were four serious adverse events of interest (three vascular access complications and one lacunar stroke). Eighty patients (98%) underwent invasive remapping. Pulsed field ablation development Cohorts 1 and 2 showed a per-patient isolation rate of 38% and 26% and a per-PV isolation rate of 47% and 53%, respectively. Optimized PFA Cohorts 3-5 showed a per-patient isolation rate of 60%, 73%, and 81% and a per-PV isolation rate of 84%, 90%, and 92%, respectively.

Conclusion: ECLIPSE AF demonstrated that optimized PFA using the CENTAURI System with three commercial, contact force-sensing, solid-tip focal ablation catheters resulted in transmural lesion formation and high proportion of durable PVI with a favourable safety profile, thus providing a viable treatment option for AF that integrates with contemporary focal ablation workflows.

Keywords: Atrial fibrillation; Focal catheter; Pulmonary vein isolation; Pulsed electric fields; Pulsed field ablation; Remapping.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.A. serves as a consultant for Galvanize Therapeutics, Boston Scientific, Farapulse, and Biosense Webster; has received grant support from Galvanize Therapeutics, Boston Scientific, Farapulse, and Biosense Webster; and owns equity in Agra MedTech, Bolt, and Future Cardia. J.V., T.P., and P.K. have received grant support from Medtronic, Boston Scientific, Biotronik, Abbott, Pfizer, Bayer, and Daiichi Sankyo. V.M. is an employee of Galvanize Therapeutics. S.G. serves as a consultant for Galvanize Therapeutics. T.B., Z.J., I.S., and L.L. have no conflicts of interest to disclose.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Configuration of the CENTAURI System in a standard EP laboratory. ECG, electrocardiogram; EP, electrophysiology.
Figure 2
Figure 2
Cohorts were established based upon ablation settings, ablation catheter, and mapping system used during the index ablation procedure.
Figure 3
Figure 3
Acute PVI and 90-day chronic PVI durability were assessed using high-density remapping to verify entrance and/or exit block. Voltage maps correlated with placement of PEF applications, and 90-day remaps confirmed no degradation of the line of block created at the index procedure. PEF, pulsed electric field; PVI, pulmonary vein isolation.
Figure 4
Figure 4
Chronic PFA lesion durability, measured by per-patient and per-PV isolation rate at 90 days, for each cohort. Patients in the PFA workflow development Cohorts 1 and 2 showed a per-patient isolation rate of 38% and 26%, and a per-pulmonary vein isolation rate of 47% and 53%, respectively. Patients in the optimized PFA Cohorts 3–5 showed a per-patient isolation rate of 60%, 73%, and 81% and a per-PV isolation rate of 84%, 90%, and 92%, respectively. There were no AEs associated with the optimization in energy settings and clinical workflows. PFA, pulsed field ablation; PV, pulmonary vein.
Figure 5
Figure 5
Points of reconnection along the PVs were addressed by delivering focal touch-up PFA using the CENTAURI System. As depicted in these examples, PV reconnections typically required minimal focal touch-up applications (a) posterior left PV carina indicated by red ablation tags, (b) epicardial sleeve posterior right carina, and (c) posterior right carina indicated by dotted ablation tags to re-isolate the vein, emphasizing the overall chronic durability of the WACAs created at the index procedure. PV, pulmonary vein; WACA, wide antral circumferential ablation.
See this image and copyright information in PMC

Comment in

References

    1. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga Let al. . 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20(1):e1–e160. - PMC - PubMed
    1. Waldo AL. Management of atrial fibrillation: the need for AFFIRMative action. Atrial fibrillation follow-up investigation of rhythm management. Am J Cardiol 1999;84:698–700. - PubMed
    1. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SLet al. . A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894–903. - PubMed
    1. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067–78. - PubMed
    1. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin Aet al. . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349–61. - PubMed

Publication types

Grants and funding